C
CALC
vs
S&P 500
S&P 500
Over the past 12 months, CALC has significantly outperformed S&P 500, delivering a return of +54% compared to the S&P 500's +12% growth.
Stocks Performance
CALC vs S&P 500
Performance Gap
CALC vs S&P 500
Performance By Year
CALC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CalciMedica Inc
Glance View
CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. The firm is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure.